[go: up one dir, main page]

PE20131165A1 - 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT - Google Patents

2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Info

Publication number
PE20131165A1
PE20131165A1 PE2013000530A PE2013000530A PE20131165A1 PE 20131165 A1 PE20131165 A1 PE 20131165A1 PE 2013000530 A PE2013000530 A PE 2013000530A PE 2013000530 A PE2013000530 A PE 2013000530A PE 20131165 A1 PE20131165 A1 PE 20131165A1
Authority
PE
Peru
Prior art keywords
fluorine substituted
antiviral treatment
halogen
alkyl
nucleosid
Prior art date
Application number
PE2013000530A
Other languages
Spanish (es)
Inventor
Aesop Chop
Choung Kim
Adrian Ray
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20131165A1 publication Critical patent/PE20131165A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (IV), DONDE R1 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; R2 ES HALOGENO; R3, R4 Y R5 SON H, HALOGENO, N3, CN, NO2, ENTRE OTROS; n ES 0 A 2; R7 ES H, C(=O)R11, S(O)R11, ENTRE OTROS; R8 ES HALOGENO, N(R11)OR11, N3, NO, ENTRE OTROS; R9 ES H, HALOGENO, NO, NO2, ENTRE OTROS; R11 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (a), (b), (c), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ARN POLIMERASA DEPENDIENTE DE ARN DEL VIRUS DE LA HEPATITIS CREFERRING TO A HETEROCYCLIC COMPOUND OF FORMULA (IV), WHERE R1 IS C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKYL, AMONG OTHERS; R2 IS HALOGEN; R3, R4 AND R5 ARE H, HALOGEN, N3, CN, NO2, AMONG OTHERS; n IS 0 A 2; R7 IS H, C (= O) R11, S (O) R11, AMONG OTHERS; R8 IS HALOGEN, N (R11) OR11, N3, NO, AMONG OTHERS; R9 IS H, HALOGEN, NO, NO2, AMONG OTHERS; R11 IS H, C1-C8 ALKYL, C2-C8 ALKYL, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: (a), (b), (c), AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF THE HEPATITIS C VIRUS

PE2013000530A 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT PE20131165A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
PE20131165A1 true PE20131165A1 (en) 2013-10-14

Family

ID=47748238

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2013000530A PE20131165A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE2022003082A PE20230684A1 (en) 2010-09-20 2011-03-22 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS AS RNA POLYMERASE INHIBITORS
PE2017001530A PE20171624A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2022003082A PE20230684A1 (en) 2010-09-20 2011-03-22 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS AS RNA POLYMERASE INHIBITORS
PE2017001530A PE20171624A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Country Status (22)

Country Link
EP (1) EP2619206A1 (en)
JP (4) JP2013538230A (en)
KR (1) KR101879887B1 (en)
CN (1) CN103108876A (en)
AP (1) AP3699A (en)
AU (1) AU2011306066B2 (en)
BR (1) BR112013008017A2 (en)
CA (1) CA2807496C (en)
CL (1) CL2013000727A1 (en)
CO (1) CO6680669A2 (en)
CR (1) CR20130172A (en)
EA (1) EA026523B1 (en)
EC (1) ECSP13012560A (en)
IL (1) IL225221A0 (en)
MA (1) MA34593B1 (en)
MX (1) MX2013003179A (en)
NZ (1) NZ608070A (en)
PE (3) PE20131165A1 (en)
PH (1) PH12013500311B1 (en)
SG (1) SG188223A1 (en)
WO (1) WO2012039791A1 (en)
ZA (1) ZA201301042B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2268642E (en) 2008-04-23 2015-06-02 Gilead Sciences Inc ANTIBODIES OF CARBON-NULCEOIDS 1-SUBSTITUTED FOR ANTIVIRAL TREATMENT
CA2773773C (en) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
KR101995598B1 (en) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
CA2822037A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv
AR088441A1 (en) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
LT2950786T (en) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
UA119050C2 (en) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. PYROL [1.2-f] [1.2.4] TRIASINES USED FOR TREATMENT OF RESPIRATORY-SYNCITAL VIRAL INFECTIONS
TWI678369B (en) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
CN104230985B (en) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 Preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate
TWI687432B (en) 2014-10-29 2020-03-11 美商基利科學股份有限公司 Methods for treating filoviridae virus infections
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX394858B (en) 2015-09-16 2025-03-24 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
EP3595672B1 (en) 2017-03-14 2023-09-06 Gilead Sciences, Inc. Compounds for use in methods of treating feline coronavirus infections
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
TW201919648A (en) 2017-07-11 2019-06-01 美商基利科學股份有限公司 Composition containing RNA polymerase inhibitor and cyclodextrin for treating viral infection
KR20240011880A (en) 2017-12-07 2024-01-26 에모리 유니버시티 N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP4096678A1 (en) 2020-01-27 2022-12-07 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
CN115298181B (en) 2020-03-12 2024-08-16 吉利德科学公司 Process for preparing 1' -cyanonucleosides
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
CA3190702A1 (en) * 2020-08-27 2022-03-03 Elaine Bunyan Compounds and methods for treatment of viral infections
CR20240363A (en) 2022-03-02 2024-10-25 Gilead Sciences Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS.
IL315733A (en) 2022-04-08 2024-11-01 SHY Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20250005322A (en) * 2022-04-25 2025-01-09 미라큐어 바이오테크놀로지 리미티드 Nucleoside drugs for the treatment or prevention of coronavirus infection and their uses
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (en) 1990-06-13 1996-04-16 Arnold Glazier PHOSPHORIC DRUGS.
ATE167679T1 (en) 1990-09-14 1998-07-15 Acad Of Science Czech Republic PHOSPHONATE PRECURSORS
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (en) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0114837A (en) 2000-10-18 2006-05-09 Pharmasset Ltd modified nucleosides for treatment of viral infections and abnormal cell proliferation
EP2360166A1 (en) 2001-01-22 2011-08-24 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
CN1849142A (en) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2'-branched nucleosides and flaviviridae mutation
RU2358979C2 (en) * 2003-05-30 2009-06-20 Фармассет, Инк. Modified fluorinated nucleoside analogues
ES2769377T3 (en) 2004-09-14 2020-06-25 Gilead Pharmasset Llc D-ribonolactone intermediates with 2-fluoro-2-alkyl substitution
CN101043893A (en) * 2004-10-21 2007-09-26 默克公司 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
CA2584367A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2673649A1 (en) 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US8440813B2 (en) 2007-01-12 2013-05-14 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
JP2011513195A (en) 2007-05-10 2011-04-28 バイオクライスト ファーマシューティカルズ， インコーポレイテッド Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
PT2268642E (en) 2008-04-23 2015-06-02 Gilead Sciences Inc ANTIBODIES OF CARBON-NULCEOIDS 1-SUBSTITUTED FOR ANTIVIRAL TREATMENT
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PE20161067A1 (en) * 2009-02-10 2016-10-23 Gilead Sciences Inc CARBA-NUCLEOSIDIC ANALOGS FOR ANTIVIRAL TREATMENT
KR101818779B1 (en) * 2009-09-21 2018-01-15 길리애드 사이언시즈, 인코포레이티드 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Also Published As

Publication number Publication date
SG188223A1 (en) 2013-04-30
CL2013000727A1 (en) 2013-08-23
CO6680669A2 (en) 2013-05-31
PH12013500311A1 (en) 2013-04-22
PE20171624A1 (en) 2017-11-02
JP2013538230A (en) 2013-10-10
JP2016074732A (en) 2016-05-12
MX2013003179A (en) 2013-04-24
MA34593B1 (en) 2013-10-02
AP3699A (en) 2016-05-31
KR20130110168A (en) 2013-10-08
AU2011306066B2 (en) 2015-01-29
KR101879887B1 (en) 2018-07-18
PE20230684A1 (en) 2023-04-21
JP2019014726A (en) 2019-01-31
BR112013008017A2 (en) 2016-06-14
EP2619206A1 (en) 2013-07-31
NZ608070A (en) 2015-11-27
WO2012039791A1 (en) 2012-03-29
AU2011306066A1 (en) 2013-02-28
CA2807496C (en) 2019-01-22
JP6475280B2 (en) 2019-02-27
CA2807496A1 (en) 2012-03-29
AP2013006767A0 (en) 2013-03-31
EA026523B1 (en) 2017-04-28
ZA201301042B (en) 2014-07-30
PH12013500311B1 (en) 2017-11-08
EA201390141A1 (en) 2013-09-30
CR20130172A (en) 2013-05-29
JP2017119726A (en) 2017-07-06
CN103108876A (en) 2013-05-15
ECSP13012560A (en) 2013-06-28
IL225221A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
PE20131165A1 (en) 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE20120995A1 (en) 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE20120257A1 (en) CARBA-NUCLEOSIDIC ANALOGS FOR ANTIVIRAL TREATMENT
CO6331439A2 (en) 1-2 BICYCLES PIRIMIDINONA CARBOXAMIDA AS INHIBITORS OF THE INTEGRESS OF THE HUMAN IMMUNODEFICIENCY VIRUS
PE20140608A1 (en) REPLACED NUCLEOTIDE ANALOGS
CY1118969T1 (en) Pyrimidine-2-amine compounds and their use as JAK kinase inhibitors
PE20171155A1 (en) METHODS AND COMPOUNDS TO TREAT VIRAL PARAMYXOVIRIDAE INFECTIONS
PE20140522A1 (en) DERIVATIVES OF NUCLEOSIDES 2'- SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
EA201590943A1 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
MA37712B1 (en) Macrocyclic inhibitors of flaviviridae virus
EA201592126A1 (en) 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
EA201000100A1 (en) HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS
EA201590384A1 (en) 6-AMINO ACID-HETEROARYDYHYDROPYRIMIDINES FOR THE TREATMENT AND PREVENTION OF INFECTION OF THE HEPATITIS B VIRUS
UY32462A (en) NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT
PE20191461A1 (en) AMIDA COMPOUNDS FOR THE TREATMENT OF HIV
PH12015501473A1 (en) Novel antiviral agents against hbv infection
AR090760A1 (en) BENZOTIAZOL COMPOUNDS AND THEIR USE AGAINST HIV VIRUS
CR10136A (en) ANTIVIRAL NUCLEOSIDS
PE20091236A1 (en) PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
AR077977A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
UY31538A1 (en) VIRICA POLYMERASE INHIBITORS
PE20211472A1 (en) DERIVATIVES OF 2- (PHENYLOXY OR PHENYLTHIUM) PYRIMIDINE AS HERBICIDES
RU2010140627A (en) Pyrrolidine derivatives
EA201600241A1 (en) SUBSTITUTED (2R, 3R, 5R) -3-HYDROXY- (5-PYRIMIDIN-1-IL) TETRAHYDROFURAN-2-ILMETYL ARIL PHOSPHORAMIDATES
EA201591328A1 (en) HETEROCYCLED SUBSTITUTED TETRICYCLIC COMPOUNDS AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES

Legal Events

Date Code Title Description
FG Grant, registration